Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRAN

Alterity Therapeutics (PRAN) Stock Price, News & Analysis

Alterity Therapeutics logo

About Alterity Therapeutics Stock (NASDAQ:PRAN)

Advanced Chart

Key Stats

Today's Range
$4.25
$4.45
50-Day Range
$0.95
$2.06
52-Week Range
$1.09
$2.91
Volume
24,175 shs
Average Volume
130,956 shs
Market Capitalization
$38.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Receive PRAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PRAN Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Alterity Therapeutics completes placement
Alterity Therapeutics announces regulatory notice
See More Headlines

PRAN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include Meta Platforms (META), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA) and Conatus Pharmaceuticals (CNAT).

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$150,000.00
Price / Cash Flow
N/A
Book Value
$1.40 per share
Price / Book
3.11

Miscellaneous

Free Float
N/A
Market Cap
$38.72 million
Optionable
Not Optionable
Beta
1.05
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:PRAN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners